Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Goldhirsch, A., Winer, E. P., Coates, A. S., Gelber, R. D., Piccart-Gebhart, M., Thürlimann, B., & Senn, H. Annals of Oncology, August, 2013. ![Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013 [link]](https://bibbase.org/img/filetypes/link.svg "link")
Paper doi abstract bibtex The 13th St Gallen International Breast Cancer Conference (2013) Expert Panel reviewed and endorsed substantial new evidence on aspects of the local and regional therapies for early breast cancer, supporting less extensive surgery to the axilla and shorter durations of radiation therapy. It refined its earlier approach to the classification and management of luminal disease in the absence of amplification or overexpression of the Human Epidermal growth factor Receptor 2 (HER2) oncogene, while retaining essentially unchanged recommendations for the systemic adjuvant therapy of HER2-positive and ‘triple-negative’ disease. The Panel again accepted that conventional clinico-pathological factors provided a surrogate subtype classification, while noting that in those areas of the world where multi-gene molecular assays are readily available many clinicians prefer to base chemotherapy decisions for patients with luminal disease on these genomic results rather than the surrogate subtype definitions. Several multi-gene molecular assays were recognized as providing accurate and reproducible prognostic information, and in some cases prediction of response to chemotherapy. Cost and availability preclude their application in many environments at the present time. Broad treatment recommendations are presented. Such recommendations do not imply that each Panel member agrees: indeed, among more than 100 questions, only one (trastuzumab duration) commanded 100% agreement. The various recommendations in fact carried differing degrees of support, as reflected in the nuanced wording of the text below and in the votes recorded in supplementary Appendix S1, available at Annals of Oncology online. Detailed decisions on treatment will as always involve clinical consideration of disease extent, host factors, patient preferences and social and economic constraints.
@article{goldhirsch_personalizing_2013,
title = {Personalizing the treatment of women with early breast cancer: highlights of the {St} {Gallen} {International} {Expert} {Consensus} on the {Primary} {Therapy} of {Early} {Breast} {Cancer} 2013},
issn = {0923-7534, 1569-8041},
shorttitle = {Personalizing the treatment of women with early breast cancer},
url = {http://annonc.oxfordjournals.org/content/early/2013/08/02/annonc.mdt303},
doi = {10.1093/annonc/mdt303},
abstract = {The 13th St Gallen International Breast Cancer Conference (2013) Expert Panel reviewed and endorsed substantial new evidence on aspects of the local and regional therapies for early breast cancer, supporting less extensive surgery to the axilla and shorter durations of radiation therapy. It refined its earlier approach to the classification and management of luminal disease in the absence of amplification or overexpression of the Human Epidermal growth factor Receptor 2 (HER2) oncogene, while retaining essentially unchanged recommendations for the systemic adjuvant therapy of HER2-positive and ‘triple-negative’ disease. The Panel again accepted that conventional clinico-pathological factors provided a surrogate subtype classification, while noting that in those areas of the world where multi-gene molecular assays are readily available many clinicians prefer to base chemotherapy decisions for patients with luminal disease on these genomic results rather than the surrogate subtype definitions. Several multi-gene molecular assays were recognized as providing accurate and reproducible prognostic information, and in some cases prediction of response to chemotherapy. Cost and availability preclude their application in many environments at the present time. Broad treatment recommendations are presented. Such recommendations do not imply that each Panel member agrees: indeed, among more than 100 questions, only one (trastuzumab duration) commanded 100\% agreement. The various recommendations in fact carried differing degrees of support, as reflected in the nuanced wording of the text below and in the votes recorded in supplementary Appendix S1, available at Annals of Oncology online. Detailed decisions on treatment will as always involve clinical consideration of disease extent, host factors, patient preferences and social and economic constraints.},
language = {en},
urldate = {2013-11-18},
journal = {Annals of Oncology},
author = {Goldhirsch, A. and Winer, E. P. and Coates, A. S. and Gelber, R. D. and Piccart-Gebhart, M. and Thürlimann, B. and Senn, H.-J.},
month = aug,
year = {2013},
pmid = {23917950},
keywords = {early breast cancer, radiation therapy, St Gallen Consensus, subtypes, Surgery, systemic adjuvant therapies},
pages = {mdt303},
file = {Full Text PDF:files/47693/Goldhirsch et al. - 2013 - Personalizing the treatment of women with early br.pdf:application/pdf;Snapshot:files/47695/annonc.mdt303.html:text/html}
}
Downloads: 0
{"_id":"yrexpA3hXgG7Cgzpi","bibbaseid":"goldhirsch-winer-coates-gelber-piccartgebhart-thrlimann-senn-personalizingthetreatmentofwomenwithearlybreastcancerhighlightsofthestgalleninternationalexpertconsensusontheprimarytherapyofearlybreastcancer2013-2013","downloads":0,"creationDate":"2016-09-09T06:27:32.659Z","title":"Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013","author_short":["Goldhirsch, A.","Winer, E. P.","Coates, A. S.","Gelber, R. D.","Piccart-Gebhart, M.","Thürlimann, B.","Senn, H."],"year":2013,"bibtype":"article","biburl":"https://www.sfu.ca/~howlett/howlett16.bib","bibdata":{"bibtype":"article","type":"article","title":"Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013","issn":"0923-7534, 1569-8041","shorttitle":"Personalizing the treatment of women with early breast cancer","url":"http://annonc.oxfordjournals.org/content/early/2013/08/02/annonc.mdt303","doi":"10.1093/annonc/mdt303","abstract":"The 13th St Gallen International Breast Cancer Conference (2013) Expert Panel reviewed and endorsed substantial new evidence on aspects of the local and regional therapies for early breast cancer, supporting less extensive surgery to the axilla and shorter durations of radiation therapy. It refined its earlier approach to the classification and management of luminal disease in the absence of amplification or overexpression of the Human Epidermal growth factor Receptor 2 (HER2) oncogene, while retaining essentially unchanged recommendations for the systemic adjuvant therapy of HER2-positive and ‘triple-negative’ disease. The Panel again accepted that conventional clinico-pathological factors provided a surrogate subtype classification, while noting that in those areas of the world where multi-gene molecular assays are readily available many clinicians prefer to base chemotherapy decisions for patients with luminal disease on these genomic results rather than the surrogate subtype definitions. Several multi-gene molecular assays were recognized as providing accurate and reproducible prognostic information, and in some cases prediction of response to chemotherapy. Cost and availability preclude their application in many environments at the present time. Broad treatment recommendations are presented. Such recommendations do not imply that each Panel member agrees: indeed, among more than 100 questions, only one (trastuzumab duration) commanded 100% agreement. The various recommendations in fact carried differing degrees of support, as reflected in the nuanced wording of the text below and in the votes recorded in supplementary Appendix S1, available at Annals of Oncology online. Detailed decisions on treatment will as always involve clinical consideration of disease extent, host factors, patient preferences and social and economic constraints.","language":"en","urldate":"2013-11-18","journal":"Annals of Oncology","author":[{"propositions":[],"lastnames":["Goldhirsch"],"firstnames":["A."],"suffixes":[]},{"propositions":[],"lastnames":["Winer"],"firstnames":["E.","P."],"suffixes":[]},{"propositions":[],"lastnames":["Coates"],"firstnames":["A.","S."],"suffixes":[]},{"propositions":[],"lastnames":["Gelber"],"firstnames":["R.","D."],"suffixes":[]},{"propositions":[],"lastnames":["Piccart-Gebhart"],"firstnames":["M."],"suffixes":[]},{"propositions":[],"lastnames":["Thürlimann"],"firstnames":["B."],"suffixes":[]},{"propositions":[],"lastnames":["Senn"],"firstnames":["H.-J."],"suffixes":[]}],"month":"August","year":"2013","pmid":"23917950","keywords":"early breast cancer, radiation therapy, St Gallen Consensus, subtypes, Surgery, systemic adjuvant therapies","pages":"mdt303","file":"Full Text PDF:files/47693/Goldhirsch et al. - 2013 - Personalizing the treatment of women with early br.pdf:application/pdf;Snapshot:files/47695/annonc.mdt303.html:text/html","bibtex":"@article{goldhirsch_personalizing_2013,\n\ttitle = {Personalizing the treatment of women with early breast cancer: highlights of the {St} {Gallen} {International} {Expert} {Consensus} on the {Primary} {Therapy} of {Early} {Breast} {Cancer} 2013},\n\tissn = {0923-7534, 1569-8041},\n\tshorttitle = {Personalizing the treatment of women with early breast cancer},\n\turl = {http://annonc.oxfordjournals.org/content/early/2013/08/02/annonc.mdt303},\n\tdoi = {10.1093/annonc/mdt303},\n\tabstract = {The 13th St Gallen International Breast Cancer Conference (2013) Expert Panel reviewed and endorsed substantial new evidence on aspects of the local and regional therapies for early breast cancer, supporting less extensive surgery to the axilla and shorter durations of radiation therapy. It refined its earlier approach to the classification and management of luminal disease in the absence of amplification or overexpression of the Human Epidermal growth factor Receptor 2 (HER2) oncogene, while retaining essentially unchanged recommendations for the systemic adjuvant therapy of HER2-positive and ‘triple-negative’ disease. The Panel again accepted that conventional clinico-pathological factors provided a surrogate subtype classification, while noting that in those areas of the world where multi-gene molecular assays are readily available many clinicians prefer to base chemotherapy decisions for patients with luminal disease on these genomic results rather than the surrogate subtype definitions. Several multi-gene molecular assays were recognized as providing accurate and reproducible prognostic information, and in some cases prediction of response to chemotherapy. Cost and availability preclude their application in many environments at the present time. Broad treatment recommendations are presented. Such recommendations do not imply that each Panel member agrees: indeed, among more than 100 questions, only one (trastuzumab duration) commanded 100\\% agreement. The various recommendations in fact carried differing degrees of support, as reflected in the nuanced wording of the text below and in the votes recorded in supplementary Appendix S1, available at Annals of Oncology online. Detailed decisions on treatment will as always involve clinical consideration of disease extent, host factors, patient preferences and social and economic constraints.},\n\tlanguage = {en},\n\turldate = {2013-11-18},\n\tjournal = {Annals of Oncology},\n\tauthor = {Goldhirsch, A. and Winer, E. P. and Coates, A. S. and Gelber, R. D. and Piccart-Gebhart, M. and Thürlimann, B. and Senn, H.-J.},\n\tmonth = aug,\n\tyear = {2013},\n\tpmid = {23917950},\n\tkeywords = {early breast cancer, radiation therapy, St Gallen Consensus, subtypes, Surgery, systemic adjuvant therapies},\n\tpages = {mdt303},\n\tfile = {Full Text PDF:files/47693/Goldhirsch et al. - 2013 - Personalizing the treatment of women with early br.pdf:application/pdf;Snapshot:files/47695/annonc.mdt303.html:text/html}\n}\n\n","author_short":["Goldhirsch, A.","Winer, E. P.","Coates, A. S.","Gelber, R. D.","Piccart-Gebhart, M.","Thürlimann, B.","Senn, H."],"key":"goldhirsch_personalizing_2013","id":"goldhirsch_personalizing_2013","bibbaseid":"goldhirsch-winer-coates-gelber-piccartgebhart-thrlimann-senn-personalizingthetreatmentofwomenwithearlybreastcancerhighlightsofthestgalleninternationalexpertconsensusontheprimarytherapyofearlybreastcancer2013-2013","role":"author","urls":{"Paper":"http://annonc.oxfordjournals.org/content/early/2013/08/02/annonc.mdt303"},"keyword":["early breast cancer","radiation therapy","St Gallen Consensus","subtypes","Surgery","systemic adjuvant therapies"],"downloads":0},"search_terms":["personalizing","treatment","women","early","breast","cancer","highlights","gallen","international","expert","consensus","primary","therapy","early","breast","cancer","2013","goldhirsch","winer","coates","gelber","piccart-gebhart","thürlimann","senn"],"keywords":["early breast cancer","radiation therapy","st gallen consensus","subtypes","surgery","systemic adjuvant therapies"],"authorIDs":[],"dataSources":["Bn7xRaKMY43f7hFwh"]}